According to Fortune Business Insights, the global bioinformatics market size was valued at USD 31.74 billion in 2025. The market is projected to grow from USD 38.45 billion in 2026 to USD 118.25 billion by 2034, exhibiting a CAGR of 15.08% during the forecast period of 2026–2034. North America dominated the global bioinformatics market with a market share of 46.23% in 2025.

Market Overview

The bioinformatics market is experiencing significant growth due to the increasing adoption of advanced data management and analytical technologies across healthcare and life sciences. Bioinformatics solutions help organizations process large volumes of biological information and identify meaningful patterns that support scientific research and clinical applications.

The technology is increasingly used in genomics, transcriptomics, metabolomics, and pharmacology. Pharmaceutical companies, biotechnology companies, contract research organizations (CROs), and research institutes use these solutions to improve research efficiency and support drug development.

Furthermore, the growing prevalence of chronic diseases is encouraging researchers to explore innovative treatment approaches. Bioinformatics platforms help analyze genomic information, identify potential drug targets, and support toxicity prediction, contributing to improvements in pharmaceutical research.

For detailed market insights: https://www.fortunebusinessinsights.com/bioinformatics-market-109493

Market Trends

Growing Adoption of Artificial Intelligence and Machine Learning

The integration of artificial intelligence (AI) and machine learning (ML) is one of the major trends shaping the bioinformatics industry. These technologies help researchers identify meaningful patterns in large and complex biological datasets. They also improve predictive models, accelerate drug discovery, and support the development of personalized medicine.

For instance, in July 2023, Genesis Healthcare introduced GenesisGaia, a generative AI platform designed to analyze genomic datasets and reduce pharmaceutical research and development bottlenecks. Similarly, FOXO Technologies Inc. launched bioinformatics services using AI-driven technologies and DNA microarray solutions to support epigenetic research.

Integration of Advanced Genomic Technologies

The growing integration of next-generation sequencing, big data analytics, and computational technologies is expanding the applications of bioinformatics. These technologies enable researchers to decode and analyze complex genomic information more efficiently, supporting advancements in disease research and precision medicine.

Market Drivers

Increasing Investment in Genomics Research

Rising investments from government and non-government organizations in genomics research are significantly supporting market growth. Researchers increasingly use whole-genome sequencing to investigate genetic diseases, identify mutations, and develop innovative treatment approaches.

For instance, in December 2022, the U.K. government invested £175 million (USD 223.02 million) in genomics research to explore whole-genome sequencing for treating genetic diseases identified in newborn babies. Such initiatives encourage the adoption of advanced bioinformatics platforms and analytical tools.

Growing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is creating demand for innovative diagnostic and treatment solutions. Pharmaceutical companies and research organizations are conducting more clinical studies to understand disease mechanisms and identify effective therapies. Bioinformatics helps process the resulting biological information and supports drug target identification, drug design, and toxicity prediction.

Increasing Clinical Research Activities

The growing volume of clinical and genomic data is encouraging healthcare organizations to adopt advanced data analysis solutions. Collaborations between research institutions and pharmaceutical companies are also increasing, supporting the development and implementation of bioinformatics technologies.

Market Segmentation

The bioinformatics market is segmented by offering, application, and end-user.

By Offering

  • Software: The software segment is expected to dominate with a 79.67% market share in 2026. Its growth is supported by the increasing adoption of sequencing platforms, analytical tools, and software solutions across research activities.
  • Services: This segment is benefiting from growing demand for specialized analytical support across clinical and research applications.

By Application

  • Genomics: The genomics segment is projected to hold a 35.29% market share in 2026, supported by increasing investments in genomic research and advancements in DNA sequencing technologies.
  • Pharmacology: Bioinformatics supports drug discovery, drug metabolism analysis, and the identification of drug-related information.
  • Metabolomics: The segment benefits from the growing use of analytical solutions to study metabolic processes.
  • Transcriptomics: These solutions help researchers analyze gene expression and related biological information.
  • Others: This category includes additional applications of bioinformatics technologies.

By End-User

  • Pharmaceutical and Biotechnology Companies: This segment is expected to account for 45.13% of the market in 2026. Growing collaborations and the integration of bioinformatics into drug discovery programs support its leading position.
  • CROs and Research Institutes: Increasing research funding and clinical study activities are supporting adoption among these organizations.
  • Others: This category includes academic institutes, hospitals, and clinics.

Key Players

The global bioinformatics market includes established technology providers and emerging companies focusing on advanced software, genomic analysis, and data management solutions. Major companies identified in the industry include:

  • DNAnexus, Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • IBM Corporation
  • LabVantage - Biomax GmbH
  • Genebio
  • Compugen Ltd.
  • Eurofins Scientific
  • QIAGEN

These companies focus on strengthening their market positions through advanced product offerings, global distribution networks, strategic partnerships, and collaborations with academic and research institutions.

For example, in January 2023, Illumina Inc. and Nashville Biosciences LLC signed an agreement with Amgen to sequence approximately 35,000 whole-genome DNA samples. In August 2023, DNAnexus collaborated with BigOmics Analytics to improve access to advanced genomic analysis and support precision medicine research.

Regional Analysis

The market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America dominated the global bioinformatics market with a 46.23% share in 2025, reaching USD 14.67 billion. The regional market is projected to reach USD 17.72 billion in 2026. Its leadership is supported by the strong presence of bioinformatics companies, established distribution networks, and increasing initiatives promoting the use of advanced analytical solutions in healthcare. The U.S. market is projected to reach USD 16.2 billion by 2026.

Europe

Europe accounted for USD 9.12 billion in 2025, representing 28.74% of global revenue. The market is estimated to reach USD 10.98 billion in 2026. Increasing investments in clinical research, genomics, personalized medicine, and advanced sequencing technologies are supporting regional expansion. The U.K. and Germany markets are projected to reach USD 2.96 billion and USD 3.00 billion, respectively, in 2026.

Asia Pacific

Asia Pacific captured 20.30% of the global market in 2025, generating USD 6.44 billion. The regional market is projected to reach USD 8.03 billion in 2026. Increasing clinical trial activities and the growing volume of clinical research data are creating demand for advanced bioinformatics tools. Japan, China, and India are projected to reach USD 3.16 billion, USD 1.88 billion, and USD 1.45 billion, respectively, in 2026.

Latin America and the Middle East & Africa

Latin America accounted for 3.05% of the global market in 2025, with a valuation of USD 0.97 billion. The market is projected to reach USD 1.13 billion in 2026. Meanwhile, the Middle East & Africa market generated approximately USD 0.53 billion in 2025, representing a 1.67% share, and is expected to reach USD 0.60 billion in 2026. Limited company presence and underdeveloped healthcare infrastructure are among the factors affecting growth in these regions.

Competitive Landscape

The competitive landscape is characterized by established companies strengthening their market presence through technological advancements, strategic alliances, and collaborations. QIAGEN, Illumina, and Agilent Technologies are among the prominent participants, supported by their product portfolios and distribution networks.

Companies are also focusing on developing innovative platforms for genomic data analysis and improving research capabilities. Partnerships between technology providers, pharmaceutical companies, and research institutions are helping expand the application of bioinformatics in drug discovery and precision medicine.

Emerging participants, including DNAnexus, Genebio, and Compugen, are also pursuing collaborations to strengthen their product offerings and expand their presence in the global market. These strategies are contributing to technological development and competition across the industry.

Future Outlook

The bioinformatics market is expected to experience substantial growth through 2034, supported by increasing genomic research investments, expanding clinical studies, and the growing adoption of AI and machine learning technologies. The rising volume of biological data will continue to create demand for advanced software platforms and specialized analytical services.

The integration of next-generation sequencing and big data analytics is expected to expand the role of bioinformatics in pharmaceutical research, disease identification, and personalized medicine. Additionally, collaborations among pharmaceutical companies, biotechnology firms, and research institutions are likely to support the development of advanced solutions.

However, the lack of standardization in data formats and analysis methods may remain a challenge. Processing large volumes of unstructured genomic and healthcare information can increase analytical complexity and delay research activities. Addressing these limitations will be important for improving adoption across the industry.

Get a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bioinformatics-market-109493

Conclusion

The global bioinformatics market is expanding as healthcare and life sciences organizations increasingly depend on advanced computational technologies to analyze complex biological information. Rising investments in genomics, increasing clinical research activities, and the integration of artificial intelligence are creating significant growth opportunities.

Software solutions and genomics applications are expected to remain important market segments, while pharmaceutical and biotechnology companies will continue to represent major end-users. Although data standardization challenges may restrict adoption, ongoing technological advancements and research collaborations are expected to support the industry's long-term development.

Frequently Asked Questions (FAQs)

1. What is the global bioinformatics market size?

Fortune Business Insights says that the global bioinformatics market was valued at USD 31.74 billion in 2025 and is projected to reach USD 118.25 billion by 2034.

2. What is the expected CAGR of the bioinformatics market?

The market is expected to grow at a CAGR of 15.08% during the forecast period of 2026–2034.

3. Which region dominates the global bioinformatics market?

North America dominated the market in 2025, accounting for 46.23% of the global market share.

4. Which segment leads the bioinformatics market by offering?

The software segment is expected to dominate, accounting for 79.67% of the global market in 2026.

5. Who are the major players in the bioinformatics market?

The major players include QIAGEN, Illumina Inc., Agilent Technologies, Thermo Fisher Scientific, IBM Corporation, DNAnexus, and Eurofins Scientific.

What’s Driving Japan’s Market? Discover the Latest Bioinformatics Market Insights

Add as a preferred source on Google